Press Releases InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
5.1 ^HKD	-1.35%		-4.67%	-25.98%

Mar. 29	InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	CI
Mar. 28	Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SF Intra-city's revenue surged 25.6% YoY to exceed RMB10 Billion	23-03-28	PR
InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong	22-12-28	AQ
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore	22-11-22	AQ
InnoCare Releases 2022 Third Quarter Results Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales	22-11-14	AQ
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China	22-09-21	AQ
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China	22-09-09	AQ
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA	22-09-06	AQ
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369	22-08-24	AQ
InnoCare Releases 2022 mid-Year Results and Business Highlights	22-08-22	AQ
InnoCare Pharma : INSIDE INFORMATION ANNOUNCEMENT COLLABORATION AND LICENSE AGREEMENT FOR TAFASITAMAB IN GREATER CHINA WITH INCYTE	21-08-16	PU
Biogen : and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis	21-07-12	AQ
InnoCare Pharma : FORM OF PROXY FOR ANNUAL GENERAL MEETING	21-05-06	PU
InnoCare Pharma : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITORS AND NOTICE OF ANNUAL GENERAL MEETING	21-05-06	PU
InnoCare Pharma : ANNOUNCEMENT - CHANGE OF NON-EXECUTIVE DIRECTORS	21-03-31	PU
InnoCare Pharma : Releases 2020 Annual Results and Business Highlights	21-03-26	PR
InnoCare Pharma : INSIDE INFORMATION PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE	21-03-11	PU
InnoCare Pharma : CHANGE OF THE CHIEF MEDICAL OFFICER	21-02-28	PU
InnoCare Pharma : to Present Clinical Data of Orelabrutinib at the Upcoming 62nd Annual Meeting of ASH	20-11-05	BU
InnoCare Pharma : Announces Clearance by the US FDA of Phase II Clinical Trial Using orelabrutinib for the Treatment of Multiple Sclerosis	20-11-02	BU
InnoCare Pharma : Appoints Dr. Manish Tandon as Vice President of Business Development	20-10-11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Press Releases

Filters